Floatz logo

Ari-0001

Acute Myeloid Leukemia

Sheba Medical CenterCell therapyPhase 2/3Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
59/ 100

Competitive context

374 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Idarubicine
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
Daunorubicin
Shen yang
Phase 4BB
ETOPOSIDE
Memorial Sloan Kettering Cancer Center
Phase 4BB
Vesanoid
The First Affiliated Hospital of Soochow University
Phase 3BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Ari-0001 is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
62 / 100
View asset →
Acute Lymphoblastic Leukemia ,LymphomasDormant
B
Indicative ·
60 / 100
View asset →
Primary Mediastinal B-cell Lymphoma (PMBCL)Dormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →